Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.

Davies JE, Berger Z, Rubinsztein DC.

Int J Biochem Cell Biol. 2006;38(9):1457-62. Epub 2006 Feb 28. Review.

PMID:
16530457
2.

Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.

Abu-Baker A, Rouleau GA.

Biochim Biophys Acta. 2007 Feb;1772(2):173-85. Epub 2006 Oct 11. Review.

3.

Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy.

Fan X, Rouleau GA.

Can J Neurol Sci. 2003 Feb;30(1):8-14. Review.

PMID:
12619777
4.

Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease.

Brais B.

Cytogenet Genome Res. 2003;100(1-4):252-60. Review.

PMID:
14526187
5.

Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Brais B.

Curr Neurol Neurosci Rep. 2009 Jan;9(1):76-82. Review.

PMID:
19080757
6.
7.

Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.

Harish P, Malerba A, Dickson G, Bachtarzi H.

Hum Gene Ther. 2015 May;26(5):286-92. doi: 10.1089/hum.2015.014. Epub 2015 May 11. Review.

PMID:
25860803
8.

Oculopharyngeal muscular dystrophy.

Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tomé FM.

Semin Neurol. 1999;19(1):59-66. Review.

PMID:
10711989
9.

The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy.

Miller JB, Girgenrath M.

Trends Mol Med. 2006 Jun;12(6):279-86. Epub 2006 May 2. Review.

PMID:
16650805
10.

Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?

Rüegg S, Lehky Hagen M, Hohl U, Kappos L, Fuhr P, Plasilov M, Müller H, Heinimann K.

Swiss Med Wkly. 2005 Oct 1;135(39-40):574-86. Review.

11.

Oculopharyngeal muscular dystrophy as a paradigm for muscle aging.

Raz Y, Raz V.

Front Aging Neurosci. 2014 Nov 10;6:317. doi: 10.3389/fnagi.2014.00317. eCollection 2014. Review.

12.
13.

[From gene to disease; the PABN1 gene and oculopharyngeal muscular dystrophy].

Schreuder AH, de Die-Smulders CE, Herbergs J, Koehler PJ.

Ned Tijdschr Geneeskd. 2006 May 20;150(20):1124-6. Review. Dutch.

PMID:
16756225
14.

Animal models in therapeutic drug discovery for oculopharyngeal muscular dystrophy.

Chartier A, Simonelig M.

Drug Discov Today Technol. 2013 Spring;10(1):e103-8. doi: 10.1016/j.ddtec.2012.07.002. Review.

PMID:
24050237
15.

Triplet repeat expansion in neuromuscular disease.

Lieberman AP, Fischbeck KH.

Muscle Nerve. 2000 Jun;23(6):843-50. Review.

PMID:
10842259
16.

PABPN1: molecular function and muscle disease.

Banerjee A, Apponi LH, Pavlath GK, Corbett AH.

FEBS J. 2013 Sep;280(17):4230-50. doi: 10.1111/febs.12294. Epub 2013 May 24. Review.

17.

Molecular mechanisms underlying polyalanine diseases.

Messaed C, Rouleau GA.

Neurobiol Dis. 2009 Jun;34(3):397-405. doi: 10.1016/j.nbd.2009.02.013. Epub 2009 Mar 6. Review.

PMID:
19269323
18.

The unresolved puzzle why alanine extensions cause disease.

Winter R, Liebold J, Schwarz E.

Biol Chem. 2013 Aug;394(8):951-63. doi: 10.1515/hsz-2013-0112. Review.

PMID:
23612654
19.

The other trinucleotide repeat: polyalanine expansion disorders.

Albrecht A, Mundlos S.

Curr Opin Genet Dev. 2005 Jun;15(3):285-93. Review.

PMID:
15917204
20.

Animal models for genetic neuromuscular diseases.

Vainzof M, Ayub-Guerrieri D, Onofre PC, Martins PC, Lopes VF, Zilberztajn D, Maia LS, Sell K, Yamamoto LU.

J Mol Neurosci. 2008 Mar;34(3):241-8. doi: 10.1007/s12031-007-9023-9. Epub 2008 Jan 18. Review.

PMID:
18202836
Items per page

Supplemental Content

Write to the Help Desk